[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Context Therapeutics Inc (CNTX)

Context Therapeutics Inc (CNTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 45,949
  • Shares Outstanding, K 91,879
  • Annual Sales, $ 0 K
  • Annual Income, $ -36,120 K
  • EBIT $ -49 M
  • EBITDA $ -49 M
  • 60-Month Beta 1.74
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.25
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.48
  • Most Recent Earnings $-0.15 on 08/05/26
  • Next Earnings Date 11/04/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.09
  • Number of Estimates 4
  • High Estimate $-0.07
  • Low Estimate $-0.11
  • Prior Year $-0.10
  • Growth Rate Est. (year over year) +10.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.4320 +15.76%
on 08/10/26
0.6949 -28.03%
on 08/05/26
-0.1299 (-20.62%)
since 07/21/26
3-Month
0.4320 +15.76%
on 08/10/26
3.1200 -83.97%
on 05/27/26
-1.8999 (-79.16%)
since 05/21/26
52-Week
0.4320 +15.76%
on 08/10/26
3.6200 -86.19%
on 03/16/26
-0.3799 (-43.17%)
since 08/21/25

Most Recent Stories

More News
Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress

Prioritization of CTIM-76 and CT-202 clinical programs, with initial clinical readouts expected beginning in Q2 2027 Cash and cash equivalents of $43.0 million as of June 30, 2026 expected to fund...

CNTX : 0.5001 (-3.77%)
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

PHILADELPHIA, July 10, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific...

CNTX : 0.5001 (-3.77%)
Context Therapeutics Added to Russell 2000® and Russell 3000® Indexes

PHILADELPHIA, July 06, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”)...

CNTX : 0.5001 (-3.77%)
Context Therapeutics Announces Positive Interim Efficacy and Safety Results from Ongoing Phase 1 Clinical Trial for CTIM-76

29% confirmed overall response rate per RECIST v1.1 in patients with platinum-resistant ovarian cancer (“PROC”) who progressed on a median of 7 prior lines of therapy Cytokine Release Syndrome...

CNTX : 0.5001 (-3.77%)
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

PHILADELPHIA, June 09, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific...

CNTX : 0.5001 (-3.77%)
Context Therapeutics to Present at the Jefferies Global Healthcare Conference

PHILADELPHIA, May 27, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific...

CNTX : 0.5001 (-3.77%)
Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202

Context announces buyout of CT-202 future milestones and royalties in exchange for a fully paid-up, non-terminable license Phase 1 initiation for CT-202 trial expected in third quarter of 2026 ...

CNTX : 0.5001 (-3.77%)
BCAB : 3.18 (unch)
Context Therapeutics Reports First Quarter 2026 Operating and Financial Results

Phase 1a interim data for ongoing CTIM-76 (CLDN6 x CD3) trial expected in June 2026 Phase 1a interim data for ongoing CT-95 (MSLN x CD3) trial expected in September 2026 Phase 1 initiation for...

CNTX : 0.5001 (-3.77%)
Neogen® Corporation Announces Appointment of Jennifer Evans Stacey as Chief Legal & Compliance Officer and Board Secretary

Neogen Corporation (NASDAQ: NEOG), an innovative leader in food safety solutions, today announced the appointment of Jennifer Evans Stacey as Chief Legal & Compliance Officer and Board Secretary. ...

CNTX : 0.5001 (-3.77%)
NEOG : 11.95 (+1.01%)
Context Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer

Fast Track Designation highlights potential of CTIM-76 to address unmet need for patients with PROC CTIM-76 Phase 1a trial ongoing, with interim data expected in June 2026 PHILADELPHIA, April...

CNTX : 0.5001 (-3.77%)

Business Summary

Context Therapeutics Inc. is a women's oncology company developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers. Context Therapeutics Inc. is headquartered in Philadelphia, PA.

See More

Key Turning Points

3rd Resistance Point 0.5782
2nd Resistance Point 0.5626
1st Resistance Point 0.5313
Last Price 0.5001
1st Support Level 0.4844
2nd Support Level 0.4688
3rd Support Level 0.4375

See More

52-Week High 3.6200
Fibonacci 61.8% 2.4022
Fibonacci 50% 2.0260
Fibonacci 38.2% 1.6498
Last Price 0.5001
52-Week Low 0.4320

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.